Abstract
Novel aspartate and succinate CGRP full antagonists were identified through core modification of a potent lead CGRP antagonist, BMS-694153. While aspartates were much less active and had a flat SAR, some of the succinates were very potent CGRP full antagonists and matched the potency of BMS-694153. The most potency resides in the S enantiomer as demonstrated through an asymmetric synthesis.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Aspartic Acid / chemical synthesis*
-
Aspartic Acid / chemistry
-
Aspartic Acid / pharmacology
-
Calcitonin Gene-Related Peptide Receptor Antagonists*
-
Humans
-
Indazoles / chemistry
-
Indazoles / pharmacology
-
Inhibitory Concentration 50
-
Molecular Structure
-
Protein Binding / drug effects
-
Quinazolinones / chemistry
-
Quinazolinones / pharmacology
-
Stereoisomerism
-
Structure-Activity Relationship
-
Succinates / chemical synthesis*
-
Succinates / chemistry
-
Succinates / pharmacology
Substances
-
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide
-
Calcitonin Gene-Related Peptide Receptor Antagonists
-
Indazoles
-
Quinazolinones
-
Succinates
-
Aspartic Acid